June Koo Lee, Heae Surng Park, Dong-Wan Kim, Kimary Kulig, Tae Min Kim, Se-Hoon Lee, Yoon-Kyung Jeon, Doo Hyun Chung, Dae Seog Heo, Woo-Ho Kim and Yung-Jue Bang Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer Cancer 118
Version of Record online: 15 NOV 2011 | DOI: 10.1002/cncr.26668
Patients who have anaplastic lymphoma kinase (ALK)-positive nonsmall cell lung cancer (NSCLC) have a poor prognosis, and their status also is predictive of primary resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors. This finding indicates that conventional treatment options do not produce favorable outcomes for patients with ALK-positive NSCLC.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field